Literature DB >> 19453990

First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.

Michael Schmidt1, Klaus Korn, C Micha Nübling, Michael Chudy, Julia Kress, Heinz A Horst, Geert Geusendam, Holger Hennig, Walid Sireis, Holger F Rabenau, Hans Wilhelm Doerr, Annemarie Berger, Michael Kai Hourfar, Knut Gubbe, Andreas Karl, Helmut Fickenscher, B Karsten Tischer, Reiner Babiel, Erhard Seifried, Lutz Gürtler.   

Abstract

BACKGROUND: In February 2007, a 63-year-old man underwent surgery. Retrospective testing with nucleic acid testing (NAT) showed that the patient was human immunodeficiency virus Type 1 (HIV-1) positive 10 days after transfusion. The transfusion-transmitted infection had been identified by a donor-related lookback started in April 2007 after anti-HIV seroconversion.
METHODS: Sequence analysis was performed in the gag-pol region as well as in the V3 loop env region. Archived plasma from the transmitting donation was investigated for the individual-donation NAT with the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 test (Roche CAP/CTM HIV-1 test) and for HIV antigen/antibody combination testing (Abbott Architect). Additional testing was done on the donor's follow-up sample and on the recipient's sample.
RESULTS: The Roche CAP/CTM HIV-1 test failed to detect viral RNA by minipool NAT in the index donation (April 2007) as well as in the donation that caused the infection (January 2007). Phylogenetic analysis showed a very high genetic similarity among viral sequences from both donor and recipient, proving the HIV-1 transmission by sequence data.
CONCLUSION: This case represents the first documented HIV-1 transmission by transfusion of red blood cells after mandatory introduction of HIV-1 NAT for blood screening in Germany. Low viral load and mismatches in the primer/probe region might explain the detection failure of the NAT screening assay. A certain risk remains that new virus variants contain mutations at positions critical for amplification or detection of viral genomes. An option to reduce the risk of a detection failure by NAT is the simultaneous use of several conserved regions as amplification targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453990     DOI: 10.1111/j.1537-2995.2009.02203.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  16 in total

1.  Pilot studies for development of an HIV subtype panel for surveillance of global diversity.

Authors:  Mark Manak; Silvana Sina; Bharathi Anekella; Indira Hewlett; Eric Sanders-Buell; Viswanath Ragupathy; Jerome Kim; Marion Vermeulen; Susan L Stramer; Ester Sabino; Piotr Grabarczyk; Nelson Michael; Sheila Peel; Patricia Garrett; Sodsai Tovanabutra; Michael P Busch; Marco Schito
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-24       Impact factor: 2.205

2.  Quality and Safety in Blood Supply in 2010.

Authors:  Rainer Seitz; Margarethe Heiden
Journal:  Transfus Med Hemother       Date:  2010-05-20       Impact factor: 3.747

3.  Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany.

Authors:  Michael Chudy; Julia Kress; Jochen Halbauer; Margarethe Heiden; Markus B Funk; C Micha Nübling
Journal:  Transfus Med Hemother       Date:  2013-12-19       Impact factor: 3.747

Review 4.  Molecular virology in transfusion medicine laboratory.

Authors:  Daniel Candotti; Jean-Pierre Allain
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

5.  Evaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors.

Authors:  Albert Heim
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

6.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

7.  Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres.

Authors:  Silke De Zolt; Rolf Thermann; Thorsten Bangsow; Lutz Pichl; Benjamin Müller; Christine Jork; Marijke Weber-Schehl; Doris Hedges; Ingo Schupp; Patrick Unverzagt; Katrin de Rue; W Kurt Roth
Journal:  Transfus Med Hemother       Date:  2016-05-11       Impact factor: 3.747

Review 8.  Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus.

Authors:  Venkatakrishna Shyamala
Journal:  Asian J Transfus Sci       Date:  2014-01

9.  The challenge of HIV-1 genetic diversity: discordant CD4+ T-Cell count and viral load in an untreated patient infected with a subtype F strain.

Authors:  Hector Bolivar; Rebeca Geffin; Gabriel Manzi; Margaret A Fischl; Vera Holzmayer; Wai-Bing Mak; Klara Abravaya; John Hackett
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.771

10.  Transmission of human immunodeficiency virus infection by renal transplantation.

Authors:  P Mukhopadhyay; V Kumar; M Rathi; H S Kohli; V Jha; V Sakhuja
Journal:  Indian J Nephrol       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.